Seagen, Astellas claim positive results in study key to cancer drug's success

Seagen and Astellas Pharma on Tuesday reported results from an important mid-stage study testing their bladder cancer drug Padcev together with Merck & Co.’s immunotherapy Keytruda in certain previously untreated patients.